Journal article

Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything

    2011
Published in:
  • Oncoimmunology. - 2012, vol. 1, no. 2, p. 227-228
English Toll-like receptor (TLR) 7 agonists represent a promising strategy for the immunotherapy of cancer. We have recently investigated the influence of TLR tolerance on the efficacy of systemic tumor treatment with TLR7 ligands. We propose that considering the kinetics of receptor sensitivity highly improves the outcome of cancer immunotherapy.
Faculty
Faculté des sciences et de médecine
Department
Département de Médecine
Language
  • English
Classification
Biology
License
License undefined
Identifiers
Persistent URL
https://folia.unifr.ch/unifr/documents/302510
Statistics

Document views: 6 File downloads:
  • bou_sci.pdf: 1